biospecimen banks

CPDR Education and Training

Academic Enrichment

 

Academic Enrichment of CPDR Trainees Through CPDR's Laboratory Meetings, Seminars and Visiting Speakers

The goal of various meetings scheduled on a weekly or monthly basis is::

  1. To enhance the quality of research
  2. To enhance interaction among CPDR researchers and trainees
  3. To follow the progress of trainees in specific research projects
  4. To learn from the experience of colleagues from other institutions
  5. To be current on the most recent discoveries in CaP and other areas of cancer research.

The CPDR supports the visits of distinguished basic science researchers in the field of prostate cancer for two of the four "CPDR Saturday" lectures on a yearly basis (special seminars). Urology residents receive CME credits for their participation in the Saturday meetings. CPDR trainees actively participate in local events such as lectures and workshops at NIH, USUHS and other research institutions in the area. Training of CPDR employees at local educational institutions is strongly encouraged in the areas that will increase their productivity at work.

 

CPDR Saturday Distinguished Speakers

Dr. Warren Heston, Cleveland Clinic (2003)
Dr. William Isaacs, Johns Hopkins University (2003)
Dr. Thomas E. Keane, Univ. South Carolina (2003)
Dr. Michael Kattan, Memorial Sloan-Kettering (2004)
Dr. Johannes Vieweg, Duke University (2004)
Dr. Paul H. Lange, University of Washington (2004)
Dr. John O. Semmes, Eastern Virginia Medical School (2004)
Dr. David E. Crawford, University of Colorado (2005)
Dr. Esther H. Chang, Georgetown University (2005)
Dr. William G. Nelson, Johns Hopkins University (2005)
Dr. Dan Theodorescu, University of Virginia (2006)
Dr. Eric A. Klein, Cleveland Clinic (2006)
Dr. Monica Leibert, AUA Office of Research (2006)
Dr. Dennis K. Watson, University of South Carolina (2006)
Dr. Nancy Dawson, Georgetown University (2007)
Dr. Chawnshang Chang, University of Rochester (2007)
Dr. Dr. Herbert Lepor, New York University Medical Center (2008)
Dr. Angelo De Marzo, Johns Hopkins University (2008)
Dr. Judd W. Moul, Duke University (2009)
Dr. Donald S. Coffey, Johns Hopkins University (2010)
Dr. John Trachtenberg, University of Toronto Ontario, Canada (2010)
Dr. S. Ward Casscells, Former Assistant Secretary of Defense (2011)
Dr. E. Shyam P. Reddy, Georgia Cancer Center for Excellence (2011)
Dr. Fritz H. Schröder, Erasmus Medical Center, the Netherlands (2012)

 

CPDR Thursday Seminar Speakers 2010-2011

Dr. Vasyl Vasko, USUHS
Dr. Deepak Kumar, UDC
Dr. Yang Du, USU
Dr. Masahiro Iwamoto, Thomas Jefferson University, PA
Dr. Suman Kapur, BITS-Pilani, Hyderabad Campus, India
Dr. Jane L. Hudak, WRAMC
Dr. Satya Saxena, Calibrant Biosystems Inc.
Dr. Arun Sreekumar, Medical College of Georgia
Dr. Steve Lincoln, Complete Genomics, Inc.
Dr. Lisa Alvis, Illumina Inc.
Dr. Kathleen S. Kelly, University of Florida
Dr. Vasan Yegnasubramanian, Johns Hopkins University
Dr. Nianxiang (Nick) Zou, AFIP
Dr. David M.Berman, Johns Hopkins Medical Institutions
Dr. Markku Miettinen, NCI, NIH
Dr. Ann Hsing, NCI, NIH
Dr. Matthew l. Freedman, Dana Farber/Harvard Cancer Center MA
Dr. Yan-gao Man, DTRC, HJF
Dr. Ani K. Jaiswal, UMD
Dr. Johnathan Meeks, Johnson & Johnson
Dr. Justin H. Johnson, Edge Bio
Dr. Yun Qiu, Maryland School of Medicine

CURRENT EVENTS


August 21, 2014

ERG Monoclonal Antibody [9FY] Patent Issued To The Uniformed Services University Of The Health Sciences Center For Prostate Disease Research & Biocare Medical

Concord, CA – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has been awarded a patent in the United States (Patent No: US 8,765,916 B2) and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada and Japan. ERG mouse antibody 9FY is a rigorously characterized antibody for its specificity of the ERG protein detection among the closely related members of the ETS transcription factor family in biological specimens.

Read Full Article

 

August 6, 2014

Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints

Redwood City, CA – PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a ...

Read Full Article

 

WRNMMC UsToo! Newsletter

Read the AUGUST 2014 Newsletter